Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: A multicenter, prospective study

Annals of Hematology

Volumn 90, Issue 10, 2011, Pages 1209-1217

  Yamaguchi, Masaki ^a   Kurokawa, Toshiro ^b   Ishiyama, Ken ^c   Aoki, Go ^a   Ueda, Mikio ^a   Matano, Sadaya ^d   Takami, Akiyoshi ^c   Yamazaki, Hirohito ^c   Sawazaki, Aiko ^e   Yamauchi, Hiromasa ^f   Yoshida, Takashi ^b   Nakao, Shinji ^c  

^a ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^b TOYAMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d TONAMI GENERAL HOSPITAL   (Japan)

^e 2 16 76 Owari cho   (Japan)

^f Kurobe City Hospital   (Japan)

Author keywords

D glucan; Aspergillus galactomannan antigen; Empirical therapy; Febrile neutropenia; Fungal infection; Micafungin

Indexed keywords

BETA GLUCAN; GALACTOMANNAN; MICAFUNGIN; ANTIFUNGAL AGENT; BACTERIAL ANTIGEN; ECHINOCANDIN; LIPOPEPTIDE; MANNAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; LIVER DYSFUNCTION; LOW DRUG DOSE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; SEROLOGY; SIDE EFFECT; SKIN TOXICITY; SURVIVAL RATE; SYSTEMIC MYCOSIS; ASPERGILLOSIS; BLOOD; BLOOD DISEASE; CLINICAL TRIAL; EARLY DIAGNOSIS; INVASIVE CANDIDIASIS; MIDDLE AGED; MYCOSIS; TOXIC HEPATITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ANTIGENS, BACTERIAL; ASPERGILLOSIS; BETA-GLUCANS; CANDIDIASIS, INVASIVE; DRUG-INDUCED LIVER INJURY; EARLY DIAGNOSIS; ECHINOCANDINS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIPOPEPTIDES; LYMPHOMA; MALE; MANNANS; MIDDLE AGED; MYCOSES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; YOUNG ADULT;

EID: 80055110558     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1277-1     Document Type: Article

References (44)

1. Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133-163 (Pubitemid 46167771)
2. Marr KA, Carter RA, Crippa F, Wald A, Corey L (2002) Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34:909-917 (Pubitemid 34229758)
3. Kume H, Yamazaki T, Abe M, Tanuma H, Okudaira M, Okayasu I (2006) Epidemiology of visceral mycoses in patients with leukemia and MDS-analysis of the data in annual of pathological autopsy cases in Japan in 1989, 1993, 1997 and 2001. Jpn J Med Mycol 47:15-24
4. Aisner J, Schimpff SC, Wiernik PH (1977) Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann Intern Med 86:539-543 (Pubitemid 8091102)
5. Morrell M, Fraser VJ, Lollef MH (2005) Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factors for hospital mortality. Antimicrob Agents Chemother 49:3640-3645 (Pubitemid 41233011)
6. EORTC International Antimicrobial Therapy Cooperative Project Group (1989) Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 86:668-672
7. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751 (Pubitemid 34194843)
8. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS, National Institute of Allergy and Infectious Diseases Mycoses Study Group (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 340:764-771 (Pubitemid 29114295)
9. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Lee J, National Institute of Allergy and Infectious Diseases Mycoses Study Group (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225-234 (Pubitemid 34438861)
10. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391-1402
11. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, Novitzky N, Boehme A, Chwetzoff E, De Beule K, Itraconazole Neutropenia Study Group (2001) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. Ann Intern Med 135:412-422 (Pubitemid 32845866)
12. Hatano K, Morishita Y, Nakai T, Ikeda F (2002) Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J Antibiot (Tokyo) 55:219-222 (Pubitemid 34285463)
13. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ (2008) In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46:150-156
14. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ (2009) In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J Clin Microbiol 47:3323-3325
15. Kohno S, Masaoka T, Yamaguchi H, Mori T, Urabe A, Ito A, Niki Y, Ikemoto H (2004) A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 36:372-379 (Pubitemid 38967695)
16. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ, Lipton J, Jacobs P, van Rensburg JH, Rex JH, Lau W, Facklam D, Buell DN (2005) International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 24:654-661 (Pubitemid 41667052)
17. Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, Ullmann AJ, Seibel NL, Flynn PM, van Burik JA, Buell DN, Patterson TF (2006) Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 53:337-349 (Pubitemid 44524711)
18. de Wet NTE, Bester AJ, Viljoen JJ, Filho F, Suleiman JM, Ticona E, Llanos EA, Fisco C, Lau W, Buell D (2005) A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 21:899-907 (Pubitemid 40477250)
19. Kuse E-R, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA, Micafungin Invasive Candidiasis Working Group (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369:1519-1527 (Pubitemid 46670281)
20. Pappas PG, Rotstein CMF, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN (2007) Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45:883-893 (Pubitemid 47580382)
21. Yanada M, Kiyoi H, Murata M, Suzuki M, Iwai M, Yokozawa T, Baba H, Emi N, Naoe T (2006) Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern Med 45:259-264
22. Toubai T, Tanaka J, Ota S, Shigematsu A, Shono Y, Ibata M, Hashino S, Kondo T, Kakinoki Y, Masauzi N, Kasai M, Iwasaki H, Kurosawa M, Asaka M, Imamura M (2007) Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies. Intern Med 46:3-9 (Pubitemid 46062246)
23. Tamura K, Urabe A, Yoshida M, Kanamaru A, Kodera Y, Okamoto Y, Maesaki S, Masaoka T (2009) Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders. Leuk Lymphoma 50:92-100
24. Kubiak DW, Bryar JM, McDonnell AM, Delgado-Flores JO, Mui E, Baden LR, Marty FM (2010) Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Therapeut 32:637-648
25. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ, Invasive Fungal Infectious Cooperative Group of the European Organization for Research and Treatment of Cancer, Mycoses Study Group of the National Institute of Allergy and Infectious Diseases (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7-14 (Pubitemid 33152659)
26. Marr KA, Balajee SA, McLsughlin L, Tabouret M, Bentsen C, Walsh TI (2004) Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 190:641-649 (Pubitemid 38982107)
27. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Munoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813-1821
28. Maertens J, Glasmacher A, Selleslag D, Ngai A, Ryan D, Layton M, Taylor A, Sable C, Kartsonis N (2005) Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. Clin Infect Dis 41:e9-e14
29. Pazos C, Ponton J, Del Palacio A (2005) Contribution of (1→3)- β-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 43:299-305 (Pubitemid 40096315)
30. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vasquez J, Pappas PG, Saeki F, Ketchum PA, Wingard J, Schiff R, Tamura H, Finkelman MA, Rex JH (2005) Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41:654-659 (Pubitemid 41170353)
31. Kawazu M, Kanda Y, Nannya Y, Aoki K, Kurokawa M, Chiba S, Motokura T, Hirai H, Ogawa S (2004) Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1→3)-β-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 42:2733-2741 (Pubitemid 38747529)
32. Masaoka T (2004) Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis 39:S49-S52 (Pubitemid 38971476)
33. de Pauw BE, Sable CA, Walsh TJ, Lupinacci RJ, Bourque MR, Wise BA, Nguyen BY, DiNubile MJ, Teppler H (2006) Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study. Transpl Infect Dis 8:31-37
34. National Committee for Clinical Laboratory Standards (2008) Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A2. NCCLS, Wayne
35. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, Rex JH, Alexander BD, Andes D, Brown SD, Chaturvedi V, GhannoumMA, Knapp CC, Sheehan DJ, Walsh TJ (2008) Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 46:2620-2629
36. Goodman D, Pamer E, Jakubowski A, Morris C, Sepkowitz K (2002) Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin Infect Dis 35: E35.E36
37. Bayramoglu G, Sonmez M, Tosun I, Aydin K, Aydin F (2008) Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin. Infection 36:68-70 (Pubitemid 351628255)
38. Matsue K, Uryu H, Koseki M, Asada N, Takeuchi M (2006) Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 42:753-757 (Pubitemid 43363927)
39. Akagi T, Yamaguti K, Kawamura T, Nakumura T, Kubo K, Takemori H (2006) Breakthrough trichosporonosis in patients with acute myeloid leukemia receiving micafungin. Leuk Lymphoma 47:1182-1183 (Pubitemid 44102991)
40. van Burik JAH, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh TJ, National Institute of Allergy and Infectious Diseases Mycoses Study Group (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39:1407-1416 (Pubitemid 39518200)
41. Usami M, Ohata HT, Nagasawa K, Wakabayashi T, Tanaka S (2002) Positive (1→3)-β-D-glucan in blood components and release of (1→3)-β-D-glucan level. Transfusion 42:1189-1195
42. Ogawa M, Hori H, Niiguchi S, Azuma E, Komada Y (2004) False-positive plasma (1→3)-β-D-glucan test following immunoglobulin product replacement in an adult bone marrow recipient. Int J Hematol 80:97-98 (Pubitemid 38937885)
43. Sulahian A, Touratier S, Ribaud P (2003) False positive test for aspergillosis antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 349:2366-2367 (Pubitemid 37509754)
44. Walsh TJ, Shoham S, Petraitiene R, Sein T, Schaufele R, Kelaher A, Murray H, Mya-San C, Bacher J, Petraitis V (2004) Detection of galactomannan antigenemia in patients receiving piperacillin. tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J Clin Microbiol 42:4744-4748 (Pubitemid 39362397)